August 2004 – The CenterWatch Monthly : Volume 11, Issue 8, August 2004
Phase I Spending Sizzles
While INDs remain flat, the phase I market is hot. Sponsors are spending more than ever in phase I on larger and more complex trials, and CROs are taking advantage of the trend toward more outsourcing of phase I. Owners of phase I units have also found it to be a seller’s market. In the short- to mid-term, a capacity crunch could emerge. The phase I market is expected to grow about 16% in 2004 to $4.1 billion, fueled by sponsors’ emphasis on becoming more efficient developing drugs by killing poor drug candidates before they enter more expensive phase II and III trials.
Foundations Venture into Clinical Research
Disease-focused foundations are motivated to become active players in the clinical research process by aiding patient recruitment and funding academic research; they are beginning to fund commercial clinical trials.
Canceropole Lyon Rhone-Alpes, a New Regional Network Fights Cancer
The decision to form Cancerpole Lyon Rhone-Alpes, a non-profit regional network comprising 15 public institutions and 35 private companies involved in cancer research and development was a followed a year of study.
Eye On: Cystic Fibrosis
Cystic fibrosis affects more than 30,000 Americans. CenterWatch has identified a pipeline of 17 drugs in development for cystic fibrosis.
- Month in Review
- In the Pipeline
- Opportunities Underway